SG11201408387YA - Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof - Google Patents
Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereofInfo
- Publication number
- SG11201408387YA SG11201408387YA SG11201408387YA SG11201408387YA SG11201408387YA SG 11201408387Y A SG11201408387Y A SG 11201408387YA SG 11201408387Y A SG11201408387Y A SG 11201408387YA SG 11201408387Y A SG11201408387Y A SG 11201408387YA SG 11201408387Y A SG11201408387Y A SG 11201408387YA
- Authority
- SG
- Singapore
- Prior art keywords
- och
- compounds
- lllll
- international
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 230000004071 biological effect Effects 0.000 title abstract 2
- 102100032187 Androgen receptor Human genes 0.000 abstract 2
- 208000027747 Kennedy disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 (substituted phenyl)-propenal moiety Chemical group 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 abstract 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 abstract 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 abstract 1
- 102220501443 Cytosolic iron-sulfur assembly component 3_C27N_mutation Human genes 0.000 abstract 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002161 motor neuron Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000155 polyglutamine Polymers 0.000 abstract 1
- 108010040003 polyglutamine Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000004700 rosacea Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/525,941 US8710272B2 (en) | 2007-01-08 | 2012-06-18 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
| PCT/US2013/046138 WO2013192091A1 (en) | 2012-06-18 | 2013-06-17 | Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408387YA true SG11201408387YA (en) | 2015-01-29 |
Family
ID=49769258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408387YA SG11201408387YA (en) | 2012-06-18 | 2013-06-17 | Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP3549581A3 (enExample) |
| JP (2) | JP6392752B2 (enExample) |
| KR (1) | KR102171469B1 (enExample) |
| CN (3) | CN106220507A (enExample) |
| AU (1) | AU2013277423B2 (enExample) |
| CA (1) | CA2876957C (enExample) |
| DK (1) | DK3150203T3 (enExample) |
| ES (1) | ES2775173T3 (enExample) |
| HK (1) | HK1211211A1 (enExample) |
| IN (1) | IN2015MN00131A (enExample) |
| MX (1) | MX2014015936A (enExample) |
| NZ (1) | NZ703167A (enExample) |
| SG (1) | SG11201408387YA (enExample) |
| WO (1) | WO2013192091A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102693361B1 (ko) * | 2017-05-26 | 2024-08-09 | 브루인 바이오사이언시스, 인크. | 화학색전제 |
| CN107226783B (zh) * | 2017-06-20 | 2019-07-23 | 武汉工程大学 | 一种溶酶体靶向荧光探针及其制备方法 |
| EP3508855A1 (en) * | 2018-01-05 | 2019-07-10 | Allianz Pharmascience Ltd | Method for the selection of patients and kit |
| GB2572259B (en) * | 2018-03-23 | 2022-03-30 | Merry Life Biomedical Company Ltd | Uses of curcumin derivative |
| JP2020117489A (ja) * | 2019-01-04 | 2020-08-06 | アリアンツ ファーマサイエンス リミテッド | 脳癌の治療方法 |
| JP2020125285A (ja) * | 2019-01-04 | 2020-08-20 | アリアンツ ファーマサイエンス リミテッド | 神経変性性障害の治療方法 |
| CN110183320B (zh) * | 2019-04-15 | 2021-06-11 | 四川大学 | 一类多烯二酮类抗肿瘤化合物 |
| EP4516771A4 (en) * | 2022-04-29 | 2025-08-20 | Nanjing Minova Pharmaceutical Co Ltd | COMPOUND HAVING ANTI-ANDROGEN RECEPTOR ACTIVITY AND ITS USE |
| CN116120182A (zh) * | 2023-02-16 | 2023-05-16 | 常州大学 | 姜黄素衍生物及其合成方法和在抗雄激素受体中的应用 |
| CN116283676B (zh) * | 2023-03-24 | 2025-03-28 | 常州大学 | 一种姜黄素衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US812408A (en) | 1905-08-19 | 1906-02-13 | Roy Ernest Dickerson | Educational device for teaching spherics. |
| US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| WO2008085984A1 (en) * | 2007-01-08 | 2008-07-17 | Androscience Corporation | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof |
| KR20100051808A (ko) * | 2007-07-31 | 2010-05-18 | 앤드로사이언스 코포레이션 | 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법 |
| US20090282496A1 (en) * | 2008-04-04 | 2009-11-12 | University Of Rochester Medical Center | Androgen Receptor Related Methods for Treating Bladder Cancer |
-
2013
- 2013-06-17 CN CN201610580850.2A patent/CN106220507A/zh active Pending
- 2013-06-17 HK HK15112031.9A patent/HK1211211A1/xx unknown
- 2013-06-17 ES ES16187672T patent/ES2775173T3/es active Active
- 2013-06-17 EP EP19176039.6A patent/EP3549581A3/en not_active Withdrawn
- 2013-06-17 CA CA2876957A patent/CA2876957C/en active Active
- 2013-06-17 CN CN201910150761.8A patent/CN110279680A/zh active Pending
- 2013-06-17 EP EP16187672.7A patent/EP3150203B1/en active Active
- 2013-06-17 SG SG11201408387YA patent/SG11201408387YA/en unknown
- 2013-06-17 JP JP2015518483A patent/JP6392752B2/ja active Active
- 2013-06-17 EP EP13806162.7A patent/EP2861222A4/en not_active Ceased
- 2013-06-17 IN IN131MUN2015 patent/IN2015MN00131A/en unknown
- 2013-06-17 KR KR1020157000948A patent/KR102171469B1/ko active Active
- 2013-06-17 DK DK16187672.7T patent/DK3150203T3/da active
- 2013-06-17 NZ NZ703167A patent/NZ703167A/en unknown
- 2013-06-17 WO PCT/US2013/046138 patent/WO2013192091A1/en not_active Ceased
- 2013-06-17 CN CN201380040213.0A patent/CN104755076A/zh active Pending
- 2013-06-17 AU AU2013277423A patent/AU2013277423B2/en active Active
- 2013-06-17 MX MX2014015936A patent/MX2014015936A/es active IP Right Grant
-
2018
- 2018-05-09 JP JP2018090272A patent/JP2018135386A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013277423A1 (en) | 2015-01-22 |
| JP6392752B2 (ja) | 2018-09-19 |
| IN2015MN00131A (enExample) | 2015-10-16 |
| CN104755076A (zh) | 2015-07-01 |
| EP2861222A4 (en) | 2015-08-05 |
| JP2015520233A (ja) | 2015-07-16 |
| HK1211211A1 (en) | 2016-05-20 |
| CA2876957A1 (en) | 2013-12-27 |
| KR102171469B1 (ko) | 2020-10-30 |
| MX2014015936A (es) | 2016-06-24 |
| KR20150023012A (ko) | 2015-03-04 |
| CN106220507A (zh) | 2016-12-14 |
| AU2013277423B2 (en) | 2018-08-09 |
| WO2013192091A1 (en) | 2013-12-27 |
| EP3549581A2 (en) | 2019-10-09 |
| EP3150203A1 (en) | 2017-04-05 |
| EP3549581A3 (en) | 2020-02-19 |
| ES2775173T3 (es) | 2020-07-24 |
| JP2018135386A (ja) | 2018-08-30 |
| CA2876957C (en) | 2021-02-16 |
| NZ703167A (en) | 2016-09-30 |
| EP2861222A1 (en) | 2015-04-22 |
| EP3150203B1 (en) | 2020-02-19 |
| CN110279680A (zh) | 2019-09-27 |
| DK3150203T3 (da) | 2020-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408387YA (en) | Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201804890TA (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201806388XA (en) | C-3 and c-17 modified triterpenoids as hiv-1 inhibitors |